| Symbol | EXEL |
|---|---|
| Name | EXELIXIS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1851 HARBOR BAY PARKWAY, ALAMEDA, California, 94502, United States |
| Telephone | +1 650 837-7000 |
| Fax | — |
| — | |
| Website | https://www.exelixis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000939767 |
| Description | Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Additional info from NASDAQ: |
Director Beckerle Mary C 🟡 adjusted position in 7.7K shares (1 derivative) of EXELIXIS, INC. (EXEL) at $48.45 Transaction Date: May 07, 2026 | Filing ID: 000063
Read moreDirector Freire Maria C 🟡 adjusted position in 20.6K shares (1 derivative) of EXELIXIS, INC. (EXEL) at $46.00 ($1.8M) Transaction Date: May 07, 2026 | Filing ID: 000062
Read moreDirector POSTE GEORGE 🔴 sold 60.0K shares of EXELIXIS, INC. (EXEL) at $45.71 ($2.7M) Transaction Date: May 07, 2026 | Filing ID: 000061
Read moreDirector MORRISSEY MICHAEL 🔴 sold 109.7K shares of EXELIXIS, INC. (EXEL) Transaction Date: May 06, 2026 | Filing ID: 000060
Read more📋 MARY BECKERLE (Director) plans to sell 8K shares of EXELIXIS, INC. (at $48.45 each, total $374K) Filed: May 07, 2026 | ID: 004211
Read more📋 GEORGE H POSTE (Director) plans to sell 60K shares of EXELIXIS, INC. (at $45.71 each, total $2.7M) Filed: May 07, 2026 | ID: 004210
Read more📋 MARIA C FREIRE (Director) plans to sell 21K shares of EXELIXIS, INC. (at $46.00 each, total $949K) Filed: May 07, 2026 | ID: 004180
Read moreExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
Read moreExelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
Read more